Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, February 17, 2023
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
[ Fri, Feb 17th 2023
] - WOPRAI
Paul Knight Maintained (WST) at Buy with Increased Target to $375 on, Feb 17th, 2023
Paul Knight of Keybanc, Maintained "West Pharmaceutical Services, Inc." (WST) at Buy with Increased Target from $315 to $375 on, Feb 17th, 2023.
Paul has made no other calls on WST in the last 4 months.
There are 3 other peers that have a rating on WST. Out of the 3 peers that are also analyzing WST, all agree with Paul's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Justin Bowers of "Deutsche Bank" Initiated at Hold and Held Target at $250 on, Wednesday, December 14th, 2022
- John Sourbeer of "UBS" Initiated at Hold and Held Target at $250 on, Wednesday, November 30th, 2022
- Derik De Bruin of "B of A Securities" Downgraded from Strong Buy to Hold and Decreased Target to $250 on, Friday, October 28th, 2022
